abiraterone,olaparib
astrazeneca,merck
['crpc', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'propel']
following the mcrpc trial propel? final analysis revealed that abi+ola extended os by &gt;7 mos compared to soc abi+placebo. even more exciting, the recorded median os (42mos) is the longest ever reported in a phase 3 1l mcrpc trial #gu23 #noeticinsight 